This kind of collective action is not without risks and must be conducted prudently, including by remaining ever vigilant about Americas capacity and willingness to underwrite a regional balancing coalition
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial
This makes it possible for anyone, no matter where they live, to get the same level of care and attention as someone in a big city
J.MeyerhofW.et al (2001)
GLP Patent Expiry Schedule - WhatsApp Image 2025-02-18 at 15.36.27_1b3ec67d1033290 42.2 KB Canada GLP Patent Protection Expiry Dates - WhatsApp Image 2025-02-19 at 09.59.19_4b03d4b71003492 112 KB STRIDES Tarriffs Coming to threat of 25% tariffs on Pharma by Trump, although it is a major issue if it really were to happen in this manner, Strides is probably one of the better placed players as they have a formulation facility in the US (Endo Pharma)
At the same time, we are facing an exciting multifaceted future, with several novel developments on the horizon with the potential to change the clinic setting, including the development of oral GLP-1 receptor agonists and the emerging formulations of GIP receptor agonists and dual and triple receptor agonists, which have shown clear therapeutic potential